That's exactly the kind of PR I was hoping the EPADI would write about the Lp-PLA2 news and V's ability to lower it - I know some folks on this board are members - any plans to write this up and put it out? I think it's a great idea, myself!
The answer to this question is crystal clear: Is the FDA ignoring heart risks from high triglycerides in the face of mounting evidence to the contrary?
The Article was written and PR'd by EPADI late June, 6 months ago. Now it clear not only is the "FDA" ignoring heart risks, but CDER (drug division) is ignoring CDRH (device division). Lp-PLA2 is a historical admittance CVD is inflamation based, something the drug community as a whole has buried the past 10 plus years.
Is the FDA ignoring science, no. Is CDER's directory, Dr. Woodcock not only ignoring Science but also another division inside the FDA? So far, yes she is.
News 
Market Data 
Discover 
